Beta Drugs Limited (NSE:BETA)

Beta Drugs Income Statement

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Revenue	3,846	3,624	2,957	2,271	1,838	1,161
Revenue Growth (YoY)	11.22%	22.54%	30.20%	23.54%	58.31%	27.88%
Cost of Revenue	2,201	2,124	1,814	1,297	1,123	722.76
Gross Profit	1,645	1,500	1,143	974.47	714.89	438.46
Selling, General & Admin	470.43	380.45	276.67	242.78	169.97	121.32
Other Operating Expenses	421.53	373.16	267.57	197.32	117.94	69.27
Operating Expenses	1,051	878.75	642.06	544.2	360.45	259.33
Operating Income	594.22	620.91	501.31	430.27	354.44	179.14
Interest Expense	-144.04	-67.41	-26.78	-22.8	-17.89	-22.2
Interest & Investment Income	51.1	51.1	10.84	6.63	4.52	3.34
Currency Exchange Gain (Loss)	-	-	0.84	-3.09	0.43	-0
Other Non Operating Income (Expenses)	68.89	10.78	1.33	-0.44	1.51	-0.74
EBT Excluding Unusual Items	570.18	615.38	487.54	410.57	343.01	159.54
Gain (Loss) on Sale of Assets	-	-	-	-	-	-0.03
Other Unusual Items	-22.22	-45.7	-	-	-	-
Pretax Income	547.95	569.69	487.54	410.57	343.01	159.51
Income Tax Expense	133.27	145.5	123.17	103.38	94.74	42.26
Net Income	414.68	424.19	364.37	307.19	248.28	117.25
Net Income to Common	414.68	424.19	364.37	307.19	248.28	117.25
Net Income Growth	-0.47%	16.42%	18.62%	23.73%	111.76%	24.53%
Shares Outstanding (Basic)	10	10	10	10	10	10
Shares Outstanding (Diluted)	10	10	10	10	10	10
Shares Change (YoY)	10.48%	5.00%	-4.76%	-	-	1.39%
EPS (Basic)	39.54	42.02	37.90	30.43	24.60	11.61
EPS (Diluted)	39.54	42.02	37.90	30.43	24.59	11.61
EPS Growth	-9.91%	10.87%	24.55%	23.74%	111.72%	22.82%
Free Cash Flow	-	-7.14	193.15	51.71	102	128.44
Free Cash Flow Per Share	-	-0.71	20.09	5.12	10.11	12.72
Gross Margin	42.78%	41.39%	38.66%	42.91%	38.89%	37.76%
Operating Margin	15.45%	17.14%	16.95%	18.95%	19.28%	15.43%
Profit Margin	10.78%	11.71%	12.32%	13.53%	13.51%	10.10%
Free Cash Flow Margin	-	-0.20%	6.53%	2.28%	5.55%	11.06%
EBITDA	741.83	734.66	599.13	534.37	426.98	247.87
EBITDA Margin	19.29%	20.28%	20.26%	23.53%	23.23%	21.35%
D&A For EBITDA	147.61	113.75	97.82	104.1	72.54	68.74
EBIT	594.22	620.91	501.31	430.27	354.44	179.14
EBIT Margin	15.45%	17.14%	16.95%	18.95%	19.28%	15.43%
Effective Tax Rate	24.32%	25.54%	25.26%	25.18%	27.62%	26.50%
Revenue as Reported	3,969	3,688	2,971	2,279	1,846	1,166
Advertising Expenses	-	35.6	14.57	12.57	8	6.74

Source: S&P Global Market Intelligence. Standard template. Financial Sources.